In Italy, the reimbursed use of incretin mimetics and incretin enhancers was subject to enrollment of patients into a web-based system recording the general demographic and clinical data of patients. We report the utilization data of glucagon-like peptide 1 (GLP1) receptor agonists and dipeptidylpeptidase-4 (DPP4) inhibitors in clinical practice as recorded by the Italian Medicines Agency (AIFA) Monitoring Registry.

Montilla, S., Marchesini, G., Sammarco, A., Trotta, M., Siviero, P., Tomino, C., et al. (2014). Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 24(12), 1346-1353 [10.1016/j.numecd.2014.07.014].

Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry

SBRACCIA, PAOLO;
2014-01-01

Abstract

In Italy, the reimbursed use of incretin mimetics and incretin enhancers was subject to enrollment of patients into a web-based system recording the general demographic and clinical data of patients. We report the utilization data of glucagon-like peptide 1 (GLP1) receptor agonists and dipeptidylpeptidase-4 (DPP4) inhibitors in clinical practice as recorded by the Italian Medicines Agency (AIFA) Monitoring Registry.
2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/09 - MEDICINA INTERNA
English
DPP4 inhibitors and GLP1 receptor agonists; Incretin-mimetics and incretin-enhancers; Monitoring registry; Real clinical practice; Type 2 diabetes; Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Female; Hemoglobin A, Glycosylated; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Triazoles; Venoms
Montilla, S., Marchesini, G., Sammarco, A., Trotta, M., Siviero, P., Tomino, C., et al. (2014). Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 24(12), 1346-1353 [10.1016/j.numecd.2014.07.014].
Montilla, S; Marchesini, G; Sammarco, A; Trotta, M; Siviero, P; Tomino, C; Melchiorri, D; Pani, L; Melchiorri, D; Marchesini, G; Sbraccia, P; Nicolucci, A; Brignoli, O; Coscelli, C; Dell'Aera, M; Mazzaglia, G; Giustini, S; De Rosa, M; Covezzoli, A; Rigazio, A; Roncadori, A
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/114913
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 36
social impact